Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Safety and efficacy study of glucarpidase for delayed clearance of methotrexate after administration of high-dose methotrexate

X
Trial Profile

Safety and efficacy study of glucarpidase for delayed clearance of methotrexate after administration of high-dose methotrexate

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Glucarpidase (Primary)
  • Indications Chemotherapy-induced damage
  • Focus Pharmacokinetics
  • Acronyms CPG2-PII
  • Most Recent Events

    • 01 Jul 2024 Results published in the Cancer Chemotherapy and Pharmacology.
    • 28 Sep 2021 According to BTG Specialty Pharmaceuticals media release, Ohara Pharmaceutical Co., Ltd. has obtained marketing authorization for glucarpidase from Japan's Ministry of Health, Labour and Welfare as a therapeutic agent for "detoxication in case of delayed methotrexate elimination with methotrexate-leucovorin rescue therapy," based on the efficacy and safety results of this study.
    • 02 Jul 2018 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top